Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In 1916 Kuo-Ching Li, a Chinese-American engineer, founded Wah Chang Trading Corporation in New York State, but it was based in Albany. He developed it as an international tungsten ore and concentrate trading company, leading the company until his death in 1961. He served as president until 1960 and then board chairman. The U.S. Bureau of Mines established Albany Research Center (ARC) on the former Albany College campus in 1942, focusing on the development of new metallurgical processes. First known as the Northwest Electro-development Facility, the site eventually produced titanium and zirconium, spearheaded by William Justin Kroll whom the bureau hired in 1945. The first zirconium strip was rolled out there in August 1946. In 1951, William Kroll joined the faculty of Oregon State College, ten miles away in Corvallis. The ARC fostered the growth of a new rare metals industry in Albany, led by internationally recognized companies such as the Oregon Metallurgical Company, Oremet, and Wah Chang. In the 1970s, Albany attempted to extend its city limits to include a zirconium processing plant of Wah Chang Corporation in order to increase its industrial tax base. Wah Chang responded in 1974 by sponsoring a vote to incorporate the desired properties as Millersburg. When the Bureau of Mines closed in 1996, the ARC was transferred to the United States Department of Energy's Office of Fossil Energy. In 2005 the facility became part of the National Energy Technology Laboratory.
=== First trial === The case attracted nationwide publicity in the United States. The trial began in February 1982. Evidence presented by the prosecution consisted of circumstantial evidence, imputation of financial motive, extensive testimony by various maids, including Maria Schrallhammer who was a prominent witness at both trials, chauffeurs, doctors, and personal exercise trainers, a black bag with drugs, and a used syringe, reported to contain traces of insulin, found in Claus von Bülow's mansion. There was much evidence of excessive use of sedatives, vitamins, and other drugs by her, including testimony of alcohol and substance abuse problems. Harvard endocrinologist George Cahill testified that he was convinced that her brain damage was the result of injected insulin. Claus von Bülow was convicted.
Steroid hormones are transported through the blood by being bound to carrier proteins—serum proteins that bind them and increase the hormones' solubility in water. Some examples are sex hormone-binding globulin (SHBG), corticosteroid-binding globulin, and albumin. Most studies say that hormones can only affect cells when they are not bound by serum proteins. In order to be active, steroid hormones must free themselves from their blood-solubilizing proteins and either bind to extracellular receptors, or passively cross the cell membrane and bind to nuclear receptors. This idea is known as the free hormone hypothesis. This idea is shown in Figure 1 to the right.
=== Circumcision === Lidocaine/prilocaine eutectic mixture has been used during circumcision in newborn boys and has been considered efficacious and safe to lessen pain from circumcision. The European Medicines Agency concludes in its latest (2014) statement on Emla: "Safety and efficacy for the use of EMLA on genital skin and genital mucosa have not been established in children younger than 12 years. Available paediatric data do not demonstrate adequate efficacy for circumcision." The Patient Information Leaflet of EMLA in the UK states: "EMLA Cream should not be applied to the genital skin (e.g. penis) and genital mucosa (e.g. in the vagina) of children (below 12 years of age) owing to insufficient data on absorption of active substances."
Sources: en.wikipedia.org
Carnivore protoparvovirus 1 is a species of parvovirus that infects carnivorans. It causes a highly contagious disease in both dogs and cats separately. The disease is generally divided into two major genogroups: the group of the classical feline panleukopenia virus (FPLV), and the group of the canine parvovirus type 2 (CPV-2), which appeared in the 1970s. Belonging to the family Parvoviridae, FPLV have linear, single-stranded DNA (ssDNA) genomes. This agent is one of the smallest animal viruses, barely 18 to 20 nm in diameter. Like other parvovirus genomes, it has hairpin structures at both ends of its genome: 3-genome Y-type structure and 5-terminal U-shaped structure, making it challenging to amplify the full-length genome of parvovirus despite its small size. Sequences in the genome show a high degree of nucleotide conservation in the VP2 gene after over 90 years since it has emerged; the VP2 gene codes for the capsid protein VP2, a main structural protein, which determines the major mutations during the evolution of CPV. FPLV is known to infect all wild and domestic members of the felid (cat) family worldwide. It is a highly contagious, severe infection that causes gastrointestinal, immune system, and nervous system disease. Its primary effect is to decrease the number of white blood cells, causing the disease known as feline panleukopenia. Although it was once thought that only FPLV caused panleukopenia in cats, it has been confirmed that a feline panleukopenia illness can be caused by CPV 2a, 2b, and 2c. FPLV is commonly referred to as:
Additionally, Lagin has written (1967 to present) a large collection of texts titled Photo/Art Notes about nature and art, photography, metaphysics, the lives of pictures, the natural history of picture world, sand drawing, creatures, enchantment, kind-ness, seeing and being seen, beauty, self-portraits, creativity, imagination, the universe, and more. From his When You Look At A Picture: when you look at a picture the picture looks at you From his Art: art is nature spirit animating form a way of being present personal individual creature to creature timeless and timefull From his The Universe Knows: the universe knows
The following is a list of events of the year 2026 in the United States, as well as predicted and scheduled events that have not yet occurred. July 4, 2026 was the 250th anniversary of the signing of the Declaration of Independence of the United States from Great Britain. Under the second year of Donald Trump's second presidency, the United States has engaged in attacks against its adversaries. In January 2026, the U.S. launched a military raid in Venezuela that captured its president Nicolás Maduro. In February 2026, the U.S. launched a major attack on Iran with Israel with the stated goal of regime change, killing its leader Ali Khamenei. Domestically, the US underwent two partial government shutdowns, with the first lasting four days, from January 31 to February 3, and the second lasting approximately 76 days, from February 14 to April 30, becoming the longest government shutdown in U.S. history and impacting the US Department of Homeland Security, with the core issue regarding the funding of Immigration and Customs Enforcement. In addition, 2026 saw the first major judicial actions against prediction markets, in particular Kalshi and the usage of its platform and other prediction markets to bypass state regulations on sports betting, with Nevada being the first to land a court-enforced ban of Kalshi and Arizona being the first to file criminal charges against Kalshi. In science and technology, the most prominent story so far has been the April 2026 NASA mission Artemis II, the first crewed deep-space mission since 1972.
=== Perey's analysis === Eka-caesium was discovered on January 7, 1939, by Marguerite Perey of the Curie Institute in Paris, when she purified a sample of actinium-227 which had been reported to have a decay energy of 220 keV. Perey noticed decay particles with an energy level below 80 keV. Perey thought this decay activity might have been caused by a previously unidentified decay product, one which was separated during purification, but emerged again out of the pure actinium-227. Various tests eliminated the possibility of the unknown element being thorium, radium, lead, bismuth, or thallium. The new product exhibited chemical properties of an alkali metal (such as coprecipitating with caesium salts), which led Perey to believe that it was element 87, produced by the alpha decay of actinium-227. Perey then attempted to determine the proportion of beta decay to alpha decay in actinium-227. Her first test put the alpha branching at 0.6%, a figure which she later revised to 1%. Perey named the new isotope actinium-K (it is now referred to as francium-223) and in 1946, she proposed the name catium (Cm) for her newly discovered element, as she believed it to be the most electropositive cation of the elements. Irène Joliot-Curie, one of Perey's supervisors, opposed the name due to its connotation of cat rather than cation; furthermore, the symbol coincided with that which had since been assigned to curium. Perey then suggested francium, after France.
=== Simplifications === In case of conservative body forces, ∇ × B = 0. For a barotropic fluid, ∇ρ × ∇p = 0. This is also true for a constant density fluid (including incompressible fluid) where ∇ρ = 0. Note that this is not the same as an incompressible flow, for which the barotropic term cannot be neglected. This note seems to be talking about the fact that conservation of momentum says
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.